Drug Trial Radar · NCT04947631
Efficacy and Safety of DKF-313 in Patients With Benign Prostatic Hyperplasia
Last checked: Nov 19, 2026Latest source record: Sep 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
667
Actual
Start
Jul 27, 2021
Primary completion
Jun 12, 2023
Study completion Jun 12, 2023
Sponsor
- Lead sponsor
- Dongkook Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 45 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, randomized, double-blinded, double-dummy, parallel group, 48-week study to evaluated the efficacy and safety of DKF-313 (dutasteride and tadalafil) in patients with benign prostatic hyperplasia.
Conditions
- Benign Prostatic Hyperplasia
Interventions
DKF-313Drug
Combination of dutasteride 0.5 mg and tadalafil 5 mg once daily for 48 weeks
DutasterideDrug
Dutasteride 0.5 mg once daily for 48 weeks
TadalafilDrug
Tadalafil 5 mg once daily for 48 weeks
DKF-313 placeboDrug
Once daily for 48 weeks
Dutasteride placeboDrug
Once daily for 48 weeks
Tadalafil placeboDrug
Once daily for 48 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Total International Prostate Symptom Score (IPSS) from baseline to Week 48Time frame: Weeks 0 and 48
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ewha Womans University mokdong Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.